BC Week In Review | Apr 15, 2013
Company News

NexMed, Zhongshan Xiaolan Pharmaceutical Factory deal

NEXM and Zhongshan formed a joint venture to manufacture, market, and distribute pharmaceuticals in China and internationally. NEXM will invest $3.5 million over the next three years and has a 70 percent controlling interest in...
BC Week In Review | Apr 8, 2013
Company News

Apricus Biosciences, Biocodex, Mist Pharmaceuticals sales and marketing update

Apricus sold commercialization rights to two programs and said it is focusing resources on commercializing Vitaros alprostadil and developing Femprox alprostadil topical cream. Apricus sold North and South American commercialization rights for Totect dexrazoxane to...
BC Week In Review | Mar 25, 2013
Company News

Apricus Biosciences supply/service news

Apricus said it will cease financing its French subsidiaries, including holding company Finesco S.A.S. and sales and marketing companies Scomedica S.A.S. and NexMed Pharma S.A.S. Apricus said the decision follows a decrease in the French...
BC Week In Review | Sep 24, 2012
Company News

Apricus Biosciences, Takeda sales and marketing update

Apricus' NexMed Inc. subsidiary granted Takeda an exclusive license to commercialize Vitaros alprostadil in the U.K. NexMed will receive an undisclosed upfront payment and is eligible for up to €35 million ($45.9 million) in milestones....
BC Extra | Feb 10, 2012
Financial News

Apricus adds $20 million

Apricus Biosciences Inc. (NASDAQ:APRI) raised $20 million through the sale of 4.9 million units at $4.05 per unit in a follow-on underwritten by Lazard; JMP Securities; and Roth Capital Partners. Each unit comprises a share...
BC Extra | Feb 9, 2012
Financial News

Array, Apricus planning follow-ons

Array BioPharma Inc. (NASDAQ:ARRY) and Apricus Biosciences Inc. (NASDAQ:APRI) each said late Wednesday they are planning follow-ons. Jefferies; Leerink; and Stifel Nicolaus Weisel are underwriting Array's offering, while Lazard is underwriting Apricus' offering. Array has...
BC Week In Review | Jul 11, 2011
Company News

Apricus Biosciences, BioTox Sciences deal

Apricus (formerly known as NexMed Inc. ) sold its Bio-Quant Inc. subsidiary to CRO BioTox for $5 million, plus up to $20 million over 10 years based on BioTox's projected revenues. Bio-Quant is a drug discovery...
BC Week In Review | Jan 3, 2011
Company News

Apricus Biosciences, Bracco S.p.A. sales and marketing update

Apricus (formerly NexMed Inc. ) granted Bracco exclusive rights to commercialize and market Vitaros alprostadil in Italy as first-line treatment of erectile dysfunction (ED). Apricus is eligible to receive up to €5.5 million ($7.2 million) in...
BC Week In Review | Nov 22, 2010
Clinical News

Vitaros alprostadil regulatory update

Health Canada approved Vitaros alprostadil from Apricus as first-line treatment of erectile dysfunction (ED). Apricus plans to launch Vitaros in Canada next year. Warner Chilcott has U.S. rights to the topical prostaglandin E1 (PGE1) cream...
BC Extra | Nov 16, 2010
Company News

Canada approves Vitaros for ED

Health Canada approved Vitaros from Apricus Biosciences Inc. (NASDAQ:APRI) for erectile dysfunction. The topical prostaglandin E1 (PGE1) cream is formulated with Apricus' NexACT transdermal delivery technology. Apricus (formerly NexMed Inc. ) gained $0.17 to $2.26 on...
Items per page:
1 - 10 of 146
BC Week In Review | Apr 15, 2013
Company News

NexMed, Zhongshan Xiaolan Pharmaceutical Factory deal

NEXM and Zhongshan formed a joint venture to manufacture, market, and distribute pharmaceuticals in China and internationally. NEXM will invest $3.5 million over the next three years and has a 70 percent controlling interest in...
BC Week In Review | Apr 8, 2013
Company News

Apricus Biosciences, Biocodex, Mist Pharmaceuticals sales and marketing update

Apricus sold commercialization rights to two programs and said it is focusing resources on commercializing Vitaros alprostadil and developing Femprox alprostadil topical cream. Apricus sold North and South American commercialization rights for Totect dexrazoxane to...
BC Week In Review | Mar 25, 2013
Company News

Apricus Biosciences supply/service news

Apricus said it will cease financing its French subsidiaries, including holding company Finesco S.A.S. and sales and marketing companies Scomedica S.A.S. and NexMed Pharma S.A.S. Apricus said the decision follows a decrease in the French...
BC Week In Review | Sep 24, 2012
Company News

Apricus Biosciences, Takeda sales and marketing update

Apricus' NexMed Inc. subsidiary granted Takeda an exclusive license to commercialize Vitaros alprostadil in the U.K. NexMed will receive an undisclosed upfront payment and is eligible for up to €35 million ($45.9 million) in milestones....
BC Extra | Feb 10, 2012
Financial News

Apricus adds $20 million

Apricus Biosciences Inc. (NASDAQ:APRI) raised $20 million through the sale of 4.9 million units at $4.05 per unit in a follow-on underwritten by Lazard; JMP Securities; and Roth Capital Partners. Each unit comprises a share...
BC Extra | Feb 9, 2012
Financial News

Array, Apricus planning follow-ons

Array BioPharma Inc. (NASDAQ:ARRY) and Apricus Biosciences Inc. (NASDAQ:APRI) each said late Wednesday they are planning follow-ons. Jefferies; Leerink; and Stifel Nicolaus Weisel are underwriting Array's offering, while Lazard is underwriting Apricus' offering. Array has...
BC Week In Review | Jul 11, 2011
Company News

Apricus Biosciences, BioTox Sciences deal

Apricus (formerly known as NexMed Inc. ) sold its Bio-Quant Inc. subsidiary to CRO BioTox for $5 million, plus up to $20 million over 10 years based on BioTox's projected revenues. Bio-Quant is a drug discovery...
BC Week In Review | Jan 3, 2011
Company News

Apricus Biosciences, Bracco S.p.A. sales and marketing update

Apricus (formerly NexMed Inc. ) granted Bracco exclusive rights to commercialize and market Vitaros alprostadil in Italy as first-line treatment of erectile dysfunction (ED). Apricus is eligible to receive up to €5.5 million ($7.2 million) in...
BC Week In Review | Nov 22, 2010
Clinical News

Vitaros alprostadil regulatory update

Health Canada approved Vitaros alprostadil from Apricus as first-line treatment of erectile dysfunction (ED). Apricus plans to launch Vitaros in Canada next year. Warner Chilcott has U.S. rights to the topical prostaglandin E1 (PGE1) cream...
BC Extra | Nov 16, 2010
Company News

Canada approves Vitaros for ED

Health Canada approved Vitaros from Apricus Biosciences Inc. (NASDAQ:APRI) for erectile dysfunction. The topical prostaglandin E1 (PGE1) cream is formulated with Apricus' NexACT transdermal delivery technology. Apricus (formerly NexMed Inc. ) gained $0.17 to $2.26 on...
Items per page:
1 - 10 of 146